Gene therapies offer massive therapeutic potential and the possibility of making clinicians' dreams of treating diseases a reality: the ability to cure genetic conditions with a one-time treatment.
In general, gene therapies introduce genetic material into a patient’s cells to correct or compensate for a genetic defect. For instance, hereditary blindness can be caused by biallelic mutations in the gene RPE65, which reduce or eliminate RPE65 activity, leading to loss of vision in childhood or adolescence. The first FDA-approved gene therapy, Luxturna (voretigene neparvovec-rzyl), delivers a normal version of the RPE65 gene directly into retinal cells, producing wild-type levels of RPE65 functioning and restoring vision loss.1
This success in 2017 opened the floodgates to gene therapy development. There is great potential to treat various inherited or acquired genetic disorders, including cancer.
While extremely promising, one of the most challenging aspects of developing a gene therapy is designing and producing a viral vector that contains the complete transgene for introduction into a cell’s nucleus. Below, we give an overview of which viral vectors are used in gene therapy development, the advantages and drawbacks of each, and how artificial intelligence is used to overcome obstacles in viral vector production.
What are Viral Vectors?
A viral vector is a virus genetically modified to deliver a specific transgene or piece of genetic material into a host cell. They are commonly used in gene therapy and vaccine development, as they can effectively transfer genetic material into cells in a controlled manner. Several types of viral vectors can be chosen depending on desired expression level, size of the transgene, the cell type that needs to be targeted, and other delivery parameters.
Common Types of Viruses Employed as Vectors to Deliver Gene Therapies
Viral vectors successfully used in the preclinical and clinical development of gene therapies include adenovirus (ADV) vectors, adeno-associated virus (AAV) vectors, and lentiviruse vectors (LV).2 Here's a quick overview of the characteristics of these viruses.
ADV is a non-enveloped DNA virus that commonly causes upper respiratory tract infections.2 There are hundreds of human ADV genotypes, and the infection cycle has been heavily studied and is known to transiently transduce nearly any mammalian cell type. The virus rarely causes severe infection in most healthy children and adults. Those infected carry lifelong immunity and express ADV-specific neutralizing antibodies.2
LVs are complex retroviruses that are spherical, enveloped, and contain a single-stranded RNA genome. Retroviruses are most commonly known for the human immunodeficiency virus, although there are several other lentiviruses that trigger persistent and chronic infection in their host. The viral particle fuses with the cell membrane upon binding to cell surface receptors, and the genome is released into the cytoplasm. Following reverse transcription, the genome is integrated into the host genome in a non-random way, favoring transcriptionally-active sites.2
Adeno-associated viruses (AAV)
AAVs are small, non-enveloped viruses that carry single-stranded DNA. It doesn’t cause any known human disease, yet it has been a popular laboratory tool as it has a relatively simple genome and can be easily manipulated. Thousands of AAV variants have been classified into a few serotypes, with differential affinities to a range of cell surface receptors.2
The Use of Viral Vectors in Gene Therapy Clinical Trials
ADV vectors in clinical trials
Adenoviral vectors are widely used in current gene therapy clinical trials and have the longest history in gene therapy, dating back to the infamous case of Jesse Gelsinger.3 This tragedy slowed the development of gene therapies for years and raised awareness about the severe innate immune response that can be generated by ADVs (specifically the capsid protein).
Nevertheless, for therapies where an immunological response is beneficial, ADV vectors showed promise: In 2003, Gendicine (an ADV vector expressing the p53 gene) was approved in China, becoming the first-ever gene therapy for cancer.2
Currently, they are being investigated clinically for novel vaccine development against infectious diseases and as cancer therapies. ADV-based vaccines against Ebola, influenza, HIV-1, and SARS-CoV-2 are all in ongoing clinical trials but haven’t navigated regulatory approval.2 ADV-based anti-cancer strategies, including delivery of suicide or regulatory genes, are also under clinical investigation.
Recently, the FDA approved the first gene therapy based on an adenoviral vector: In December 2022, Adstiladrin was approved for the treatment of high-risk non-muscle invasive bladder cancer resistant to Bacillus Calmette-Guérin.4
LV vectors in clinical trials
LV vectors have been primarily used for engineering ex vivo gene therapies, such as generating chimeric antigen receptor T (CAR-T) cells.2 The first FDA-approved ex vivo gene therapy, Kymriah, transduced autologous T cells with an LV vector carrying a CAR transgene that binds CD19 and was used to treat pediatric B-cell relapsed and refractory acute lymphoblastic leukemia.8 Other ex vivo therapies that target different cancers are being investigated, and as proof of the safety of LV vectors becomes available, the number of trials will continue to increase.2
AAV vectors in clinical trials
AAV-based gene therapies are being investigated in several rare diseases and there have been over 200 clinical trials worldwide using AAVs.2 Due to small patient populations and limited enrollment, clinical study of AAV-based therapies is slow and limited to diseases with no other treatment options. Clinical trials are ongoing for age-related and diabetic macular degeneration (AMD), muscular dystrophies, hemophilia, and X-Linked myotubular myopathy (XLMTM)2.
While some trials have produced promising results, there have also been several noteworthy trials that have been halted due to safety concerns: A high-dose AAV vector for treating XLMTM was recently linked to the deaths of three patients.5 These challenges will need to be addressed should AAV therapies continue to be commercialized.
The FDA has approved three AAV-based therapies (as of January 2023): Luxturna for retinal dystrophy, Zolgensma for spinal muscular atrophy, and recently, Hemgenix for the treatment of adults with Hemophilia B (congenital Factor IX deficiency).1,6,7
Opportunities and Challenges of the Different Viral Vectors for Gene Therapy Development Programs
Using ADV, AAV, and LV vectors in gene therapy development has distinct advantages and drawbacks. Choosing the right vector type depends on the transgene, desired expression level, target cell type, and therapeutic application.2
Opportunities and Challenges of ADV Vectors
ADV vectors are often the preferred choice for gene therapies due to their high transduction efficiency, stability in host cells, capacity (up to 4 kb for first generation, up to 10kb for second generation and up to 36 kb for third-generation vectors), and ability to target various tissues2.
However, ADVs also have some significant drawbacks. Many people have been previously infected with ADVs and therefore have pre-existing immunity that can lead to strong immune responses to the viral vector or transgene products.2 These safety concerns limit the use of ADVs to diseases that are not impacted by immune responses or even rely on the target cells being killed (e.g., in cancer treatment).
Opportunities and Challenges of LV Vectors
LVs are often used to deliver transgenes due to their ability to integrate into the host genome effectively, express multiple transgenes (up to 9 kb) for long periods from a single vector, and infect non-dividing cells.10 They also tend to have a low immunogenicity profile.
However, there is a risk of generating a replication-competent virus, particularly with LVs derived from HIV-1. To address this risk, third-generation vectors have been developed that do not have the genes required for genome packaging. Still, LVs have high mutation and recombination rates, which can pose a small but significant risk. One primary concern is the accidental generation of an oncogene, which is why LV vectors are only used in ex vivo applications, such as CAR-T therapy, and not in vivo therapies.
Opportunities and Challenges of AAV Vectors
AAVs are versatile and stable, with a lifespan of over 10 years in differentiated cell populations.9 Moreover, AAVs are capable of transducing a broad range of dividing and non-dividing cell types which makes then an attractive vector for gene delivery purposes.
However, AAVs have a limited capacity of around 5 kb, which has led to developing strategies such as split vector approaches to address this limitation. Like ADVs, AAVs can also cause immune responses that must be considered during discovery and development. Additionally, converting the single-stranded DNA genome into double-strand DNA, which is required for transduction in host cells, can be a rate-limiting step.
AAVs can also be difficult for tissue-specific transgene expression, and their production can be challenging to scale up economically. Read on to hear how Form Bio is leading the field with cutting edge artificial intelligence strategies to overcome these challenges.
Solving the AAV Viral Vector Biomanufacturing Problem with Artificial Intelligence
The clinical successes and regulatory approvals of gene therapies sets up a bright future for continued research, development, and improvement of how clinicians treat genetic disorders. However, many viral vector candidates in clinical trials face complications, particularly in the biomanufacturing where viral construct design problems delay the journey to commercialization.
Applying advances in artificial intelligence (AI) to the viral vector construct design issues is unlocking transformational breakthroughs in biomanufacturing efficiency and success. Here's how.
DNA and Protein Feature Prediction
Recently, large language models (LLMs) have been applied to DNA sequence analysis, enabling accurate functional prediction (e.g., promotors, enhancers, etc.). This allows viral construct designers to foresee gene expression complications using sequence analysis alone11. As reviewed in our previous blog, LLMs can be further applied to protein analysis, giving cell and gene therapy developers the ability to accurately predict development and biomanufacturing outcomes12.
Epigenetic and Variant Effect Prediction
Deep learning architectures – trained on epigenetic and transcriptional datasets – have been utilized to yield precise gene expression prediction13.The ML algorithms use long-range interactions, as far as 100 kb away, for accurately forecasting the impacts of mutations and methylation. Again, these methods can be directly applied to construct optimization for viral vectors.
Truncation Propensity Prediction
A major issue in viral vector biomanufacturing, specifically with adeno-associated viruses (AAVs), is the incomplete packaging of the viral genome into a capsid. These “truncated” AAVs reduce the potency and purity of AAV preparations. AI can help in modeling and predicting truncation by identifying DNA sequences associated with truncation. This provides developers with insights that enable the optimization of constructs with a reduced propensity for truncation, improving the manufacturability of AAV-based gene therapies.
The development of a neural network model has been able to, with high accuracy, predict where truncations during viral packaging can occur, further validating the utility of machine learning in gene therapy development.14 In doing so, machine learning has been useful in solving a multi-billion dollar industry problem that plagues nearly all AAV gene therapy developers.
Viral vectors play a crucial role in the development of gene therapies and different types of viral vectors can be used depending on the specific requirements of the therapy. ADVs, LVs and AAVs have all been used successfully in preclinical and clinical gene therapy trials.
While there are potential challenges and risks associated with the use of viral vectors, such as the innate immune response, the potential benefits of gene therapies make them a worthwhile area of continued research and development. With the implementation and acceptance of artificial intelligence into the gene therapy development workflow, commercialization will continue to become more streamlined and cost-effective, making powerful therapeutics more readily available to the patients that need them15.